Skip to content
Companies

Parcel Biosciences

Nanoparticle-free mRNA delivery to specific cells

  • San Francisco, CA
  • Founded 2024
  • Biotech

Raised to date

$13.2M

of $13.2M offered across 1 Form D filing

Investors
52
Last filed
Mar 4, 2026

About

Parcel Biosciences is a seed-stage biotechnology startup founded in 2023, focused on developing next-generation RNA therapeutics. The company is creating a nanoparticle-free delivery system for mRNA medicines, aiming to overcome the technical limitations of current lipid nanoparticle technologies. This innovative approach is designed to enable targeted delivery of therapeutics to specific cell types, expanding the potential applications of mRNA beyond vaccines.

The company's core innovation is its STAmP™ platform, a delivery system that protects mRNA from degradation without using nanoparticles. This method allows for precise, cell-specific targeting and is designed to be safer for systemic applications and higher doses compared to traditional delivery technologies.

Funding

  • EquityFiled Mar 4, 2026Form D
    $13.2M/ $13.2M

Product

STAmP™ (Stabilization and Targeting by Annealing mRNA to ParcelOligos) Platform

mRNA Delivery Platform

The STAmP™ platform is a non-viral, nanoparticle-free delivery system for mRNA. It utilizes chemically modified oligonucleotides, called ParcelOligos, which anneal directly to the mRNA payload. This process stabilizes the mRNA and allows for the attachment of targeting ligands (such as GalNAc or C16) to guide the therapeutic to specific cells and tissues.

  • Provides mRNA stability without encapsulation in lipid nanoparticles
  • Enables precise, cell-specific targeting via customizable ligands
  • Designed to support higher therapeutic doses and systemic applications

Built for

Pharmaceutical and biotechnology companies

People on file